Endovastec(SH:688016) Sou Hu Cai Jing·2026-01-13 11:57Core Viewpoint - Xinmai Medical (688016) has shown mixed financial performance with a slight increase in revenue but a significant decline in net profit for the first three quarters of 2025 [2] Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a total revenue of 1.015 billion yuan, representing a year-on-year increase of 4.66% [2] - The net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The net profit excluding non-recurring items fell by 25.8% to 372 million yuan [2] - In Q3 2025, the company achieved a quarterly revenue of 300 million yuan, marking a substantial year-on-year increase of 64.68% [2] - The quarterly net profit attributable to shareholders was 114 million yuan, down 23.63% year-on-year [2] - The quarterly net profit excluding non-recurring items was 102 million yuan, a decline of 11.84% [2] - The company's debt ratio stands at 15.85%, with investment income of 11.6 million yuan and financial expenses of -7.8584 million yuan [2] - The gross profit margin is reported at 70.4% [2] Market Activity - As of January 13, 2026, Xinmai Medical's stock closed at 98.82 yuan, with a slight increase of 0.39% [1] - The trading volume was 26,400 hands, with a total transaction value of 262 million yuan [1] - The net inflow of main funds was 7.5162 million yuan, accounting for 2.87% of the total transaction value [1] - Retail investors experienced a net outflow of 14.0856 million yuan, representing 5.38% of the total transaction value [1] Analyst Ratings - Over the past 90 days, eight institutions have provided ratings for Xinmai Medical, with seven giving a "buy" rating and one an "increase" rating [2] - The average target price set by institutions in the last 90 days is 1.3603 billion yuan [2]